Table 2.

Hazard ratios for the associations between HFE genotype group and the risk of cancer

CANCER	allele	C282Y copies	cases	Person years	HR§	95 % CI	P‖
COLORECTAL (stratified by sex)	Co-dominant	0	530	326,019	ref·		0·02
		1	80	53,275	0·88	0·67, 1·14
		2	10	2,566	2·28	1·22, 4·25
	Recessive	0 or 1	610	379,294	ref·		0·01
		2	10	2,566	2·31	1·24, 4·32
	with H63D	0	530	326,019	ref·		0·04
		1 (no H63D)	61	44,017	0·92	0·73, 1·17
		1 (& 1 H63D)	19	9,233	1·27	0·80, 2·01
		2	10	2,566	2·28	1·22, 4·25
BREAST (female only)	Co-dominant	0	565	188,991	ref·		0·03
		1	90	31,238	0·93	0·73, 1·20
		2	9	1,245	2·39	1·24, 4·61
	Recessive	0 or 1	655	220,229	ref·		0·01
		2	9	1,245	2·40	1·24, 4·63
	with H63D	0	565	188,991	ref·		0·09
		1 (no H63D)	71	25,805	0·96	0·77, 1·20
		1 (& 1 H63D)	19	5,433	1·16	0·74, 1·84
		2	9	1,245	2·39	1·24, 4·61
PROSTATE	Co-dominant	0	646	121,404	ref·		0·84
		1	106	19,585	1·04	0·83, 1·30
		2	6	1,159	0·96	0·43, 2·15
	Recessive	0 or 1	752	140,989	ref·		0·91
		2	6	1,159	0·96	0·43, 2·14
	with H63D	0	646	121,404	ref·		0·96
		1 (no H63D)	87	16,220	1·02	0·83, 1·26
		1 (& 1 H63D)	19	3,364	1·08	0·68, 1·70
		2	6	1,159	0·96	0·43, 2·15
ANY OTHER NON-HAEMATOLOGICAL CANCER♣ (stratified by sex)	Co-dominant	0	1510	289,434	ref·		0.58
		1	234	47,498	0.92	0.79, 1.07
		2	12	2,163	1.01	0.57, 1.78
	Recessive	0 or 1	1744	336,932	ref·		0.96
		2	12	2163	1.02	0.58, 1.79
	with H63D	0	1510	289,434	ref·		0.39
		1 (no H63D)	188	39,419	0.94	0.82, 1.08
		1 (& 1 H63D)	46	8,080	1.11	0.82, 1.48
		2	12	2,163	1.01	0.57, 1.78
ANY CANCER (stratified by sex)	Co-dominant	0	3441	320,421	ref·		0·11
		1	548	52,519	0·96	0·86, 1·06
		2	36	2,451	1·30	0·93, 1·80
	Recessive	0 or 1	3989	372,940	ref·		0·12
		2	36	2,451	1·30	0·94, 1·81
	with H63D	0	3441	320,421	ref·		0·09
		1 (no H63D)	439	43,486	0·97	0·89, 1·06
		1 (& 1 H63D)	109	9,033	1·13	0·93, 1·36
		2	36	2,451	1·30	0·93, 1·80

^§Analysis used Cox regression with age as the primary timescale but included no other potential confounders

^♣The catagory comprises all cancers bar colorectal, breast (female), prostate and haematological cancers

^‖P-values were generated from the likelihood ratio test, which was used to compare a model assuming a separate risk parameter for each HFE genotype to the null model assuming no HFE genotype effect on the risk of cancer. The “Co-dominant” model classifies HFE genotype based on the C282Y mutation alone (likelihood ratio test with 2 d.f.) whereas the “With H63D” model further classifies those with one copy of the C282Y mutation into those who do and do not have a copy of the H63D mutation (likelihood ratio test with 3 d.f..)